Cebranopadol

Cebranopadol is a novel analgesic drug that acts as an agonist at the nociceptin receptor (NOP) and the mu-opioid receptor (MOR). It is being investigated for its potential use in the treatment of chronic pain and other pain-related conditions.
Pharmacology[edit]
Cebranopadol is unique in its dual mechanism of action, targeting both the nociceptin receptor and the mu-opioid receptor. This dual action is believed to provide effective pain relief while potentially reducing the risk of opioid-induced side effects such as respiratory depression, tolerance, and dependence.
Nociceptin Receptor[edit]
The nociceptin receptor, also known as the opioid receptor-like 1 (ORL1) receptor, is involved in the modulation of pain and other physiological processes. Agonists at this receptor can produce analgesic effects without the typical side effects associated with traditional opioids.
Mu-Opioid Receptor[edit]
The mu-opioid receptor is the primary target for most opioid analgesics, including morphine and fentanyl. Activation of this receptor leads to potent analgesic effects but also carries a high risk of side effects such as addiction, constipation, and respiratory depression.
Clinical Trials[edit]
Cebranopadol has undergone several clinical trials to evaluate its efficacy and safety in the treatment of various types of pain, including neuropathic pain, cancer pain, and osteoarthritis. Results from these trials suggest that cebranopadol is effective in reducing pain intensity and has a favorable safety profile compared to traditional opioids.
Potential Benefits[edit]
The dual mechanism of action of cebranopadol may offer several potential benefits over traditional opioids:
- Reduced risk of respiratory depression
- Lower potential for tolerance and dependence
- Effective in treating a wide range of pain conditions
Side Effects[edit]
While cebranopadol is generally well-tolerated, some common side effects reported in clinical trials include:
Conclusion[edit]
Cebranopadol represents a promising new approach to pain management, offering effective analgesia with a potentially improved safety profile compared to traditional opioids. Ongoing research and clinical trials will further elucidate its role in the treatment of chronic pain and other pain-related conditions.
See Also[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian